Purpose: To determine the prevalence of professionally reported oral side effects of chemotherapy and the self-reported oral side effects and whether both prevalences could be related to the periodontal risk of the patients.
Methods: A cross-sectional study with patients undergoing chemotherapy treatment was carried out. Demographic, oral hygiene habits, and cancer-related data were collected while the patient was receiving the chemotherapy infusion. Patient's oral status, measured according to the oral-assessment guide for patients in hospital environments, patient-related outcomes (PROMs), measured by a visual analogue scale, and patient's periodontal risk were analyzed using validated questionnaires. Data was reported in means and standard deviations (SD) in quantitative variables and in counts, prevalence, and 95% confidence intervals (CI) in qualitative variables. ANOVA test and chi-squared tests were used to compare oral side effects among different periodontal risk groups.
Results: Three hundred sixty-nine patients were included in the study. The prevalence of professionally reported oral side effects was 86.99% (95% confidence interval CI 83.54%; 90.44%). The prevalence of self-reported oral side effects was 89.70% (95% CI 86.59; 92.82). The most common oral side effects were xerostomia (73.4%), dysgeusia (61.8%), and dry lips (54.2%). More oral alterations were found in patients with worse periodontal risk (p < 0.001).
Conclusions: The prevalence of oral side effects (professional or self-reported) is higher than 85% in patients undergoing chemotherapy. This prevalence increases as the risk of developing periodontal disease does.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00520-019-4650-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effects of Shenqi Xiangyi granules in advanced gastric cancer chemotherapy.
World J Gastrointest Oncol
January 2025
Department of Oncology, Zhangjiagang First People's Hospital, Suzhou 215600, Jiangsu Province, China.
Background: Owing to the absence of specific symptoms in early-stage gastric cancer, most patients are diagnosed at intermediate or advanced stages. As a result, treatment often shifts from surgery to other therapies, with chemotherapy and targeted therapies being the primary options for advanced gastric cancer treatment.
Aim: To investigate both treatment efficacy and immune modulation.
The Role of Intravenous Selexipag in Managing PAH and Bridging Gaps in Oral Treatment: A Narrative Review.
Ther Clin Risk Manag
January 2025
Departments of Medicine and Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY, USA.
Pulmonary arterial hypertension (PAH) is a rare and potentially fatal condition characterized by progressive increases in blood pressure in the arteries of the lungs. Oral selexipag, approved by the Food and Drug Administration (FDA) in 2015 for the treatment of PAH, targets prostacyclin receptors on pulmonary arterial vascular smooth muscle and endothelial cells to improve blood flow through the lungs and reduce pulmonary vascular resistance. Oral selexipag is effective, but may be discontinued due to factors like side effects, emergency conditions, or inability to take oral medication, potentially leading to severe adverse events, such as rebound pulmonary hypertension and right heart failure.
View Article and Find Full Text PDFThe Impact of Orthodontic Treatment on Body Weight Due to Change in Dietary Habits.
Cureus
December 2024
Orthodontics, Sardar Begum Dental College and Hospital, Gandhara University, Peshawar, PAK.
Background Orthodontic treatment, while primarily focusing on correcting dental alignment and occlusion, has been increasingly validated for its potential impact on broader aspects of oral health and general well-being: its potential influence on body weight. While the mechanical effects of orthodontic appliances are well documented in the literature, their potential behavioral impact on weight loss remains underexplored. Beyond its primary role in correcting dental alignment, our study has unveiled a lesser-known benefit: its potential to aid in weight reduction among individuals who have already struggled through conventional methods.
View Article and Find Full Text PDFSequence and Chronology of Permanent Teeth Eruption in 5-18-Year-Old School Children of Chennai and the Influence of Sex, BMI, and Socio-Economic Status.
Am J Hum Biol
January 2025
Department of Public Health Dentistry, Tamilnadu Govt Dental College, Chennai, India.
Objectives: This study aimed to determine the sequence and eruption chronology of permanent teeth in school children and adolescents of Chennai and compare the findings with an existing standard table. Additionally, the study also attempted to explore the influence of sex, body mass index (BMI), and socioeconomic status (SES) on tooth eruption patterns.
Methods: A cross-sectional study was designed, and 12,650 children aged 5-18 years were selected from thirty-five schools using a multistage random sampling method.
Safety and Efficacy of Selexipag for Pediatric Pulmonary Arterial Hypertension in Japanese Patients - An Open-Label Phase 2 Study.
Circ J
January 2025
Department of Echo-imaging Center, Aizawa Hospital.
Background: Selexipag, an oral prostacyclin (PGI) receptor agonist, is approved for adult patients with pulmonary arterial hypertension (PAH). This study evaluated the efficacy and safety of selexipag for Japanese pediatric patients with PAH.
Methods And Results: The study enrolled 6 patients who received selexipag twice daily at an individualized dose based on body weight; maintenance doses were determined for each patient by 12 weeks after starting administration.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!